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Using EpiLymph case-control data, we found that chronic
lymphocytic leukemia patients were more likely to have
abnormal reactive serological patterns to Epstein Barr virus
than controls. Here, we aimed to assess whether this associa-
tion is modified by genetic variants. We examined 1,305 Single
Nucleotide Polymorphisms from 300 selected genes related to
various pathways in 240 cases and 513 controls from five
European centers. In a recessive model, patients positive to
aberrant antibody pattern and homozygous for rare genotypes
in rs8113877T>G or rs17576A>G of the MMP9 gene were at
highest risk of chronic lymphocytic leukemia. In a dominant
model, TP73 showed the highest risk in patients positive to
aberrant antibody pattern and homozygous for the wild-type
genotype in rs1885859G>C or rs3765701A>T. All interactions
were additive and no main effect was observed. The strong
interactions observed may be indicative of a specific pathway
in cancer genesis. Confirmation of these results is warranted. 
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ABSTRACT
Introduction
Chronic lymphocytic leukemia (CLL), one of the common-
est forms of lymphoid malignancies, is characterized by an
accumulation of abnormal B-cells in the peripheral blood.
Chronic lymphocytic leukemia patients were three times
more likely to have aberrant anti-Epstein Barr virus antibody
(ab_EBV) patterns than controls.1 Recent prospective data
supported this association.2 Monoclonal B-CLL tumors are
generally EBV negative and frequently arise from the sub-
group of CD5+ B cells, which are resistant to EBV infection.
Chronic inflammation or antigen triggering may lead to loss
of homeostatic B-cell control and outgrowth of a malignant B-
cell clone, particularly in the elderly. Epstein Barr virus, which
is normally well controlled by host immune responses but can
be sub-clinically reactivated by a variety of stress signals,
might trigger B-cell activation.3 Such Epstein Barr virus reacti-
vation is reflected by aberrant Epstein Barr virus seroreactivi-
ty. This process might become functional in the background
of “minor” genetic defects that increase the chance of erro-
neous events over time. The increased chronic lymphocyt-
ic leukemia risk in individuals with antibody signature of
Epstein Barr virus reactivation, as reflected in an increased
antibody diversity1,2 might reflect such an indirect role of
Epstein Barr virus in chronic lymphocytic leukemia patho-
genesis.
To further analyze the role of genetic susceptibility
markers, we selected 1,305 single nucleotide polymor-
phisms (SNPs) from 300 genes associated with inflamma-
tion, apoptosis, immunoregulation, cell-cycle, metabolic
and DNA-repair pathways, and examined their interaction
with abnormal reactive serological patterns to Epstein Barr
virus among 240 chronic lymphocytic leukemia patients
and 513 controls from EpiLymph.  
Design and Methods
Study population 
The design of the EpiLymph study has been described in detail
elsewhere.1 Briefly, the Czech Republic, France, Ireland, Italy,
Germany and Spain took part from 1998 to 2003, using a compa-
rable questionnaire and study protocol. Overall, the study includes
2,362 incident lymphoma cases and 2,465 controls. Chronic lym-
phocytic leukemia and small lymphocytic lymphoma were
grouped and classified according to the World Health
Organization (WHO) classification.4 Patients with organ trans-
plantation or HIV infection were excluded from analysis. The large
majority of chronic lymphocytic leukemia cases were untreated at
the time of blood collection. The study was approved by the
Research ethics committee and all patients gave their consent to
participate in the study.  
Laboratory methods
Detailed information on Epstein Barr virus serology has been
reported elsewhere.1 Genomic DNA was quantified using
PicoGreen and diluted to a final concentration of 50 ng/AL.
Genotyping was performed using a customized Illumina Golden
Gate genotyping assay (Illumina Inc., San Diego, USA) and all SNP
genotype data were manually clustered using BeadStudio soft-
ware (Illumina).  
Candidate gene choice and SNP selection
In selecting candidate genes, we aimed at SNPs located in genes
coding for innate immunity, specifically in NFKB and TLR signal-
ing, other immunoregulatory and apoptosis pathways, and cell
cycle regulation.  Also genes predisposing for diseases associated
with an elevated risk of lymphoma and susceptibility to infectious
agents were considered. A list of all investigated polymorphisms
along with their MAP and Hardy-Weinberg Equilibrium (HWE) P
values can be found in the Online Supplementary Appendix 1.
SNP genotyping and exclusions 
Individual exclusions criteria
Overall, 241 chronic lymphocytic leukemia cases and
518 controls from EpiLymph were genotyped for this
study. Following the exclusion of 3 samples that had less
than 95% individual call rate and 3 subjects due to discrep-
ancy between sex call from X chromosome genotype data
and self-reported data, 240 chronic lymphocytic leukemia
cases (including 6 small lymphocytic lymphoma) and 513
controls were included in the analysis. There was no dif-
ference between the proportion of cases and controls
excluded due to low call rate (0.04% vs. 1.00%, P
value=0.43, for cases and controls, respectively).  
Marker exclusions criteria
Of the 1,419 SNPs that were selected for genotyping, 114 were
excluded (one monomorphic SNP, 27 SNPs from X chromosome,
82 SNPs with call rate less than 95% and 4 SNPs with HWE less
than 1¥10-6 among controls). For all control patients, minor allele
frequency was over 1%. 
Statistical analysis 
Using STATA10 (StataCorp, USA), genotypic distributions of
each SNP were assessed for Hardy-Weinberg Equilibrium among
controls using exact c2 goodness of fit test. Logistic regression
models adjusted for age (tertiles based on the control age distribu-
tion), sex and country were used to estimate the odds ratio for
chronic lymphocytic leukemia by each SNP, haplotypes,
ab_Epstein Barr virus status and for the main effects of each SNP
with detected interaction.  All statistical tests were two-sided. 
Dominant and recessive inheritance models were examined.
Statistical interactions using multiplicative and additive scales
were considered. Two tests of significance, HA0 and HM0, were used
to assess departure towards multiplicative or additive interactions,
respectively.5 Data on interactions were presented in a two-by-
four table format. Based on these two derived P values, interac-
tions were defined as additive, multiplicative, both or neither.
Interactions were considered as genuine if HA0 and/or HM0 were
rejected at the 5% level in Spain and Germany separately (the 2
countries with the most data). Matched analysis on age (-/+ 2
years), sex and center was also performed as a sensitivity analysis.
The haplotype block structure was determined with Haploview
4.1 software. Haplotypes and haplotype pairs were reconstructed
using the haplo.stats package for R statistical software
(http://www.r-project.org/). 
Results and Discussion
The characteristics of the 240 chronic lymphocytic
leukemia patients and 513 controls are shown in Table 1.
A higher proportion of cases than controls were men (P=
0.10) and the mean age was 63.8 years (standard deviation
(SD) 9.5) in cases and 63.1 years (SD 11.7 years) in con-
trols. The proportion of individuals with aberrant reaction
to antibodies against Epstein Barr virus was 20% in con-
trols and 39% in cases. 
Four SNPs were found to interact with ab_EBV in chron-
ic lymphocytic leukemia risk (Table 2). All interactions
were additive.  In a recessive model, two MMP9 SNPs
(rs8113877 and rs17576) were found to modify the effect
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Table 1. Characteristics of CLL cases and controls.
Characteristics                                Control                   CLL                     Total 
                                                      (n= 513)              (n= 240)              (n= 753)
Age, mean (SD)                                    63.1 (11.7)               63.8 (9.5)               63.3 (11.0)
Male/female ratio (n)                       1.2 (281/232)           1.7 (151/89)           1.3 (432/321)
Ab_EBV, number positive (%)            100 (20)                   94 (39)                   194 (26)
Hospital-based, n (% total)a                371 (72)                  138 (58)                  509 (68)
Spain, number                                         295                             72                             367
France, number                                       58                              33                              91
Czech Republic, number                       18                              33                              51
Population-based, n (% total)a            142 (28)                  102 (43)                  244 (32)
Germany, number                                  135                             94                             229
Italy, number                                             7                                8                               15
n: number; Ab_EBV: aberrant EBV activity; SD: Standard deviation. aBased on control
Table 2. Adjusted1 odds ratio (and 95% confidence interval) for CLL by SNPs and ab_EBV positivity with P valueHA0 or HM0 ≤0.05 in Germany and Spain
separately using recessive and dominant models.
ALL COUNTRIES SPAIN GERMANY 
Ab_EBV Gene (SNPs) - Cases – controls OR1(95% CI) Cases – controls OR1 (95% CI) Cases – controls OR1 (95% CI)
status2 model and Number (%) Number (%) Number (%) 
genotype (N= 240/513) (N= 72/292) (N= 94/135)
MMP9 (rs8113877) – recessive
Neg TT/TG 129 (54%) - 332 (65%) Ref 41 (57%) - 184 (62%) Ref 46 (49%) - 87 (64%) Ref
Neg GG 17 (7%) - 80 (16%) 0.54 (0.30 to 0.99) 6 (8%) - 53 (18%) 0.48 (0.19 to 1.21) 2 (2%) - 14 (10%) 0.30 (0.06 to 1.40)
Pos TT/TG 72 (30%) - 87 (17%) 2.16 (1.45 to 3.22) 19 (26%) - 50 (17%) 1.64 (0.86 to 3.15) 32 (34%) - 28 (21%) 2.17 (1.15 to 4.09)
Pos GG 22 (9%) - 11 (2%) 6.25 (2.81 to 13.90) 6 (8%) - 5 (2%) 7.34 (1.98 to 27.19) 14 (15%) - 6 (4%) 4.95 (1.72 to 14.23)
P valueHA0 or HM0 0.08 / 0.002 (A) 0.2 / 0.01 (A) 0.2 / 0.04 (A)
MMP9 (rs17576) – recessive
Neg AA/AG 131 (55%) - 351 (69%) Ref 40 (56%) - 197 (67%) Ref 46 (49%) - 90 (67%) Ref
Neg GG 14 (6%) - 62 (12%) 0.62 (0.32 to 1.19) 6 (8%) - 41 (14%) 0.64 (0.25 to 1.65) 2 (2%) - 11 (8%) 0.39 (0.08 to 1.87)
Pos AA/AG 77 (32%) - 94 (18%) 2.26 (1.53 to 3.34) 20 (28%) - 54 (18%) 1.81 (0.95 to 3.42) 35 (38%) - 31 (23%) 2.23 (1.21 to 4.12)
Pos GG 16 (7%) - 6 (1%) 8.83 (3.22 to 24.17) 5 (7%) - 3 (1%) 9.53 (2.04 to 44.57) 10 (11%) - 3 (2%) 7.47 (1.88 to 29.61)
P valueHA0 or HM0 0.1 / 0.004 (A) 0.3 / 0.03 (A) 0.3 / 0.05 (A)
TP73  (rs3765701) – dominant
Neg AA 44 (18%) - 167 (33%) Ref 16 (22%) - 93 (32%) Ref 12 (13%) - 42 (31%) Ref
Neg AT/TT 102 (43%) - 245 (48%) 1.74 (1.13 to 2.67) 31 (43%) - 144 (49%) 1.36 (0.69 to 2.67) 36 (38%) - 59 (44%) 2.51 (1.15 to 5.51)
Pos AA 40 (17%) - 26 (5%) 6.68 (3.53 to 12.62) 14 (19%) - 15 (5%) 6.43 (2.47 to 16.70) 15 (16%) - 6 (4%) 10.11 (3.14 to 32.56)
Pos AT/TT 54 (22%) - 72 (14%) 3.09 (1.83 to 5.21) 11 (15%) - 41 (14%) 1.56 (0.65 to 3.76) 31 (33%) - 28 (21%) 4.30 (1.86 to 9.93)
P valueHA0 or HM0 0.07 / 0.005 (A) 0.1 / 0.02 (A) 0.3 / 0.03 (A)
TP73 (rs1885859) – dominant
Neg GG 46 (19%) - 174 (34%) Ref 18 (25%) - 94 (32%) Ref 15 (16%) - 45 (34%) Ref
Neg GC/CC 99 (41%) - 237 (46%) 1.72 (1.12 to 2.62) 29 (40%) - 143 (48%) 1.24 (0.64 to 2.41) 33 (35%) - 55 (41%) 1.95 (0.93 to 4.09)
Pos GG 48 (20%) - 34 (7%) 6.13 (3.42 to 10.99) 16 (22%) - 22 (7%) 4.45 (1.88 to 10.55) 22 (23%) - 8 (6%) 8.50 (3.07 to 23.54)
Pos GC/CC 46 (19%) - 66 (13%) 2.75 (1.62 to 4.68) 9 (13%) - 35 (12%) 1.44 (0.58 to 3.60) 24 (26%) - 26 (19%) 3.06 (1.34 to 6.97)
P valueHA0 or HM0 0.04 / 0.003 (B) 0.1 / 0.06 (A) 0.2 / 0.03 (A)
OR: odds ratio, CI: confidence interval, NA: not available, ref: reference. 1based on logistic regression adjusted for age, sex and country (if appropriate). 2Neg and Pos: negative and positive
to aberrant antibody response against EBV, respectively. 3All interactions were tested for additive and multiplicative effects. Two tests of significance, HA0 and HM0, were used to assess departure
towards multiplicative or additive interactions, respectively. Based on these two derived P values, interactions were defined as additive (A), multiplicative (M), both (B) or neither (N).
of ab_EBV on chronic lymphocytic leukemia (P val-
ues=0.002 and 0.004 for rs8113877 and rs17576, respec-
tively). Overall, ab_EBV positive individuals were more
likely to develop chronic lymphocytic leukemia compared
to those who were negative, independently of their geno-
type. Compared to ab_EBV positive carriers of TT/TG and
AA/AG for the MMP9 SNPs rs8113877 and rs17576,
respectively, individuals carrying the GG genotype and
being positive to ab_EBV were more likely to have been
diagnosed with chronic lymphocytic leukemia. By con-
trast, among ab_EBV negative patients, the presence of
both rare alleles (GG) decreased significantly the odds
ratio for chronic lymphocytic leukemia. In a dominant
model, two TP73 SNPs (rs3765701 and rs1885859) modi-
fied the association between ab_EBV and chronic lympho-
cytic leukemia (P values=0.005 and 0.003 for rs3765701
and rs1885859, respectively). Odds ratio of chronic lym-
phocytic leukemia were significantly higher among all
groups compared to ab_EBV negative carriers of wild-type
homozygous genotypes. Antagonist effects were
observed among ab_EBV positive patients with carriers of
the wild-type homozygous genotypes having higher sig-
nificant odds ratio of chronic lymphocytic leukemia than
those with other genotypes. Restricting the analyses to
chronic lymphocytic leukemia patients with lower Rai
stage did not materially change the results suggesting that
clinical stage does not confound the observed association
(Online Supplementary Appendix 2). Matched analysis
decreased the power of the study but did not substantially
alter the results (Online Supplementary Appendix 3). A list of
SNPs with HA0 and/or HM0 rejected at the 10% level in
Spain and Germany separately are shown in the Online
Supplementary Appendix 4.
The same data as Table 2 were displayed based on mul-
tiple contingency tables (Figure 1). Here, odds ratios of
chronic lymphocytic leukemia in ab_EBV positive com-
pared to ab_EBV negative patients are shown according to
the genotype of the four SNPs. Overall, the odds ratio of
chronic lymphocytic leukemia in all ab_EBV positive
patients compared to all ab_EBV negative patients was
2.76 (95% CI=1.91 to 3.98). The odds ratios of chronic
lymphocytic leukemia associated with ab_EBV positivity
were significantly higher among carriers of the GG
homozygous genotypes for the 2 MMP9 SNPs than in
those without this genetic characteristic. In relation to the
two TP73 polymorphisms and based on a dominant
SNPs of MMP-9 and TP73 interact with ab_EBV in CLL
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model, odds ratio of chronic lymphocytic leukemia asso-
ciated with ab_EBV was higher among carriers of the
homozygous genotypes AA and GG compared to those
with the AT/TT or GC/CC for rs3765701 and rs1885859.
Haplotype analyses and LD plots of the genotyped SNPs
of the MMP9 and TP73 genes are shown in the Online
Supplementary Appendices 5, 6 and 7, respectively. All five
MMP9 gene variants were in strong linkage disequilibri-
um. Overall, the haplotype pair analysis for MMP9 sup-
ported the results observed in single SNP analysis. In par-
ticular, a significant greater odds ratio of chronic lympho-
cytic leukemia in relation to ab_EBV was found with the
haplotype pair Hap2-Hap3 where each haplotype includes
two copies of the rare allele G (Wald test P=0.00005).
Using Hapmap (Phase II, NCBI B36, dbSNP b126) we
found that the SNPs rs1885859 and rs3765701 of the TP73
were in strong linkage disequilibrium (D’=0.93; r²=0.453)
and decided to include the borderline results for SNP
rs3765701 with the main results. 
A role for Epstein Barr virus activation in the etiology
and progression of chronic lymphocytic leukemia is
increasingly discussed.6,7 Epstein Barr virus control
requires a constant lifelong state of alert of the immune
system, involving approximately 1% of all T cells, which
may decrease with increasing age.8 A raised EBV-reactiva-
tion with age may be reflected in an increased incidence of
EBV-driven lymphoproliferative diseases and B-cell lym-
phomas in the elderly.9 Various stress factors can trigger
Epstein Barr virus reactivation,8 evoking immune respons-
es that are reflected in a broadened spectrum of anti-EBV
antibodies. Transcriptional activity of the Epstein Barr
virus latent membrane protein 1 (LMP1) with known
transforming potential in vitro was recently detected in a
significant proportion of chronic lymphocytic leukemia
patients.7 Atypical Epstein Barr virus serological patterns1,2
appear to be associated with chronic lymphocytic
leukemia and its clinical grade independently of age
(Online Supplementary Appendix 8). Monoclonal B-CLL are
generally EBV negative and the role of Epstein Barr virus,
if any, would probably be indirect via B-cell triggering and
facilitation of malignant growth.1 By considering that a
major effect in the carcinogenic process was determined
by presence of ab_EBV, genetic factors were evaluated as
risk modifiers.
MMP9 belongs to a family of zinc-dependent endopep-
tidases which degrade type IV collagen, a major compo-
nent of the basement membrane which is involved in
tumor growth, apoptosis, angiogenesis, invasion and
metastasis.10 The SNP rs17576 has been previously associ-
ated with chronic lymphocytic leukemia in a large popu-
lation-based case-control study11 using recessive models.
MMP9 is activated and over-expressed in B-cell chronic
lymphocytic leukemia.12 Importantly, MMP9 is induced
by EBV-encoded oncogene Latent Membrane Protein 1
(LMP1)13 and is further stimulated by Epstein Barr virus
lytic switch protein ZEBRA that also stimulates LMP1 re-
expression.14 LMP1 of Epstein Barr virus has been found to
induce MMP9 expression in lymphoblastoid cells14 and in
EBV-immortalized B lymphocytes.15 In particular, nuclear
antigen 3C (EBNA3C) proteins up-regulate MMP9 in B
cells from Burkitt’s lymphoma16 and multiple myeloma
cells.17 MMP9 proteins might interact with Epstein Barr
virus proteins to maintain a microenvironment supporting
the proliferation of B cells18 and, in particular, angiogenesis
through migration, proliferation and invasion of B-CLL
cells might play an important indirect role in malignant
growth of chronic lymphocytic leukemia disease.19
TP73 belongs to the transcription factor p53 family
(together with p63) and maps to the p36 region of chro-
mosome 1, a region frequently deleted in neuroblastoma
and other tumors20 and affected by chromosomal aberra-
tions, including insertions, deletions, and Copy Number
Variation.21 To our knowledge, none of the TP73 polymor-
phisms that we reported here have been examined in pre-
vious epidemiological studies. In relation to Epstein Barr
virus, molecular studies have shown that silencing of TP73
by hypermethylation is associated with EBV-related gas-
tric cancer while no consistent association is observed in
C. Casabonne et al.
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Figure 1.  Adjusted odds ratio
and 95% confidence intervals of
chronic lymphocytic leukemia in
relation to ab_EBV status,
according to genotype of MMP9-
rs8113877, MMP9-rs17576,
TP73-rs1885859 and TP73-
rs3765701.
EBV-negative gastric cancer.22 EBV-associated lymphoid
malignancies such as Burkitt’s lymphoma23 have also been
associated with methylation of TP73. 
It has to be stressed that our results might simply reflect
the play of chance given the large number of performed
tests. Further potential limitations of this study include
hospital-based controls which could introduce some selec-
tion biases. The strengths of the EpiLymph study lie in its
multi-center dimension that allows validation across
countries with large differences in ab_EBV positivity.
Unfortunately, none of the SNPs that have been associated
with chronic lymphocytic leukemia in recent Genome
Wide Association studies was genotyped for this study.24
None of the four SNPs was found to be associated with
chronic lymphocytic leukemia as a main effect (Online
Supplementary Appendix 9), suggesting that the presence of
both risk factors (genetic and environmental) might be
necessary to act on the disease. Analyses of interactions
are crucial to better understand the complexity of the eti-
ology of chronic lymphocytic leukemia. Our preliminary
findings, therefore, suggest novel pathways in lymphoma-
genesis and deserve to be validated.
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